With Latest Data, Investors Again Compare Synergy To The Billion-Dollar Ironwood Pharma

Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data, presented at a medical meeting on Monday, for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.